- SLIDES-AUDIO LECTURECME
-
Author(s)/Faculty: Eric M. Ruderman, MD; Leonard H. Calabrese, DO; Stanley B. Cohen, , MD; Jeffrey Curtis, MD, MS, MPH Source: Type: Multimedia Articles/Items: 3 Release Date: 10/13/2015 Expiration Date: 10/12/2016 Credit Type: CME Number of Credit(s): 1 Cost: Free CME Provider: - Methotrexate (MTX) has served as the cornerstone of rheumatoid arthritis (RA) therapy for decades. However, with new and emerging biologic and small molecule disease modifying antirheumatic drugs (DMARDs) entering the therapeutic scene, more options are now available for patients refusing to take MTX or those experiencing MTX intolerance or inadequate response. In this expert panel, recent data comparing mono- and combination therapy will re-evaluate the role of the various DMARDs in the initiation and maintenance of RA treatment, explore emerging methods of personalizing therapy, and delve into therapeutic options after initial biologic DMARD failure.
- This activity is supported by an educational grant from Genentech, Inc.
Support Statement: This activity is supported by an educational grant from Genentech, Inc.
Target Audience: The intended audience for the activities is rheumatologists and other health care professionals involved in the treatment of patients with rheumatoid arthritis (RA).
Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:
- Apply evidence-based approaches when selecting initial therapies for patients with RA.
- Optimize treatment approaches for patients with RA who do not respond adequately to anti-TNF agents.
- Employ personalized treatment regimens for patients with RA in scenarios where the use of methotrexate (MTX) is contraindicated or ineffective.
Activity Chair:
Eric M. Ruderman, MD
Professor of Medicine
Division of Rheumatology
Northwestern University Feinberg School of Medicine
Chicago, IL
Faculty:
Leonard H. Calabrese, DO
Professor of Medicine, Cleveland Clinic Lerner
College of Medicine of Case Western Reserve University
RJ Fasenmyer Chair of Clinical Immunology
Theodore F Classen D.O. Chair of Osteopathic Research and Education
Vice Chairman, Department of Rheumatic and Immunologic Diseases
Cleveland, OH
Stanley B. Cohen, MD
Clinical Professor, Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology, Presbyterian Hospital—Dallas
Co-Medical Director, Metroplex Clinical Research Center
Dallas, TX
Jeffrey Curtis, MD, MS, MPH
University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology
William J. Koopman Endowed Professor in Rheumatology and Immunology
Director, UAB Arthritis Clinical Intervention Program
Co-Director, UABCenter for Education and Research on Therapeutics (CERTS)
Co-Director, UAB PharmacoEpidemiology and Economic Research (PEER) Group
Birmingham, AL
Peer Reviewer:
Kevin Deane, MD
This enduring material is approved for 1 year from the date of original release, October 13, 2015 to October 12, 2016.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Faculty reports the following relationship(s):
Eric M. Ruderman, MD
Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Medac, Novartis, Pfizer, Pharmacyclics, Vertex
Fees for Non-CE Services Received Directly From a Commercial Interest or its Agents: AbbVie
Contracted Research: AbbVie, Amgen, Pfizer, Pharmacyclics
Leonard H. Calabrese, DO
Consulting Fee: GSK, Janssen, Pfizer, Sanofi
Speakers Bureau: AbbVie, BMS, Crescendo, Genentech, Janssen
Stanley B. Cohen, MD
No relevant financial relationships to disclose.
Jeffrey Curtis, MD, MS, MPH
Consulting Fee: AbbVie, Amgen, BMS, Corrona, Crescendo, Genentech/Roche, Janssen, Pfizer, UCB
Peer Reviewer reports the following relationship(s):
Kevin Deane, MD
No relevant financial relationships to disclose.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.